Showing results (71-80 of 321) with videos related to
Sort By:
Pageof 33
Blood|July 31, 2020
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotypeDavid A Sallman, Amy F McLemore, Amy L Aldrich, et al.Cancer Research|March 31, 2025
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative EffectNancy Klemm, Roman R Schimmer, Nils K Konrad, et al.Blood|August 18, 2023
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancyPeter G Miller, Adam S Sperling, Christina Mayerhofer, et al.Blood Advances|September 28, 2021
CXCL12-abundant reticular cells are the major source of IL-6 upon LPS stimulation and thereby regulate hematopoiesisRahel C Gerosa, Steffen Boettcher, Larisa V Kovtonyuk, et al.Blood|May 2, 2015
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromesDavid P Steensma, Rafael Bejar, Siddhartha Jaiswal, et al.Elife|April 10, 2019
Intergenerational epigenetic inheritance of cancer susceptibility in mammalsBluma J Lesch, Zuzana Tothova, Elizabeth A Morgan, et al.Blood|March 10, 2005
An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarrayBenjamin L Ebert, Michele M Lee, Jennifer L Pretz, et al.Blood|April 30, 2011
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesisAnupama Narla, Shilpee Dutt, J Randall McAuley, et al.Science (New York, N.Y.)|August 10, 2019
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignanciesSteffen Boettcher, Peter G Miller, Rohan Sharma, et al.Blood|June 20, 2023
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cellsBing Z Carter, Po Yee Mak, Muharrem Muftuoglu, et al.Pageof 33